Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025 Recently Approved Treatments Give High Market Potential

Aug 03, 2015, 09:00 ET from Visiongain

LONDON, August 3, 2015 /PRNewswire/ --

Ovarian Cancer Therapies - Explore Potentials of New Drugs, Industry Changes and Emerging Opportunities
What's the future for treating cancer of the human ovaries? Visiongain's new study forecasts those pharmaceutical revenues. There you find outlooks for sales growth in that industry. You also explore trends, results, treatments, R&D, and opportunities, seeing prospects.

Our report gives revenue predictions to 2025 at overall world market, submarket, product and national level. So avoid falling behind in data or losing influence. Instead discover, from 2015, what progress, opportunities and results are possible for those cancer treatments.

Read on, then, to explore ovarian cancer therapy and see what future revenues that pharma market could generate.

Forecasts and other analysis to benefit your research, assessments, plans and decisions
With our new study you explore prospects for companies developing, producing and marketing drugs for treating cancer of the ovaries. See present trends and future possibilities.

Besides revenue forecasting to 2025, our new work shows recent results, sales growth rates and market shares. There you find original analysis. Assess research and development too, seeing prospects. Also get 57 tables, 57 charts and three interviews with companies.

So avoid missing out on original data and discussions to help your work.

Treating ovarian tumours - find R&D and sales growth opportunities, helping your work
Our study's purpose is to help your research, analyses and decisions on those therapies, also benefiting your authority and reputation for insight.

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

The future holds high promise for organisations treating that gynaecological disorder. Discover the progress and gains possible there, avoiding struggles to find business information you need. See how patients, healthcare providers and companies can benefit.

Visiongain's analysis finds the ovarian cancer treatments market evolves, as new drugs enter the market and promising R&D pipeline candidates reach late-stage clinical trials. Discover what revenues are possible from 2015 in that expanding pharma segment.

Opportunities for pharmaceutical companies open there, giving high sales potentials. Our new study finds that market can achieve strong revenue growth from 2015 to 2025, driven by expanding patient populations and revenues from recent and expected product launches.

Though no such study covers everything, the following sections show how our new investigation benefits your work.

Forecasting that world market and sub-segments for treating ovarian cancer
What are the secrets of that technology's progress? And what potential does it have? Find in our report overall world revenue to 2025 for those antineoplastic medicines - existing, emerging and expected drugs.

Also explore individual revenue predictions to 2025 for four therapeutic submarkets at world level:
• Chemotherapy
• Targeted therapies
• Immunotherapy
• Hormonal treatments.

Where lie the best sales potentials? With our analysis you assess outlooks for revenue expansion, seeing where you can gain. Also investigate competitors' actions and prospects.

See how those cancer-treating medicines develop, hearing where needs and business opportunities exist. With a growing incidence of ovarian cancer and high recurrence and mortality rates, the demand for better treatments will continue to bolster that drug market.

You also find sales predictions by product, exploring how they can succeed.

Predictions of leading products' sales - what's possible for those cancer-treating drugs?
How will individual medicines perform from 2015 to 2025 at world level? Our study forecasts ovarian cancer treatment revenues of these three brands:
• Avastin (bevacizumab)
• Lynparza (olaparib).
• Yondelis (trabectedin).

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

There you discover how high sales can go, finding medicines and years with highest predicted revenues. Also examine competition. That way you investigate what's happening, understanding challenges, trends, competitors and opportunities.

Discover what the future holds. Our work also shows you geographical predictions, by country.

Healthcare in national markets - what outlooks for ovarian cancer drug revenues?
Advances in the biopharma industry and market expand the use of drugs to treat ovarian cancer. Discover those technologies' international sales prospects.

Our work shows you individual revenue forecasts to 2025 for 11 national markets:
United States (US)
Japan
Germany, France, the United Kingdom (UK), Italy and Spain (EU5 group)
Brazil, Russia, India and China (BRIC countries).

You assess countries with highest revenues and potential growth. Explore outlooks for treating that disease, including patients' and healthcare providers' needs. That way you find opportunity in treating ovarian tumours. See what the future holds for companies.

You also examine developments leading to novel treatments.

R&D for those cancer therapies - developmental trends, innovations and progress
In our study you investigate that oncology - research and development on ovarian tumours. You examine these advances and others, seeing clinical progress and what it means:
• PARP inhibition
• Biologically enhanced chemotherapeutics
• Tumour vascular disruption
• Angiokinase inhibition
• Cytotoxic technology based on pyrrolobenzodiazepine
• Luteinising hormone-releasing hormone (LHRH) therapy
• Polyvalent antigen-KLH conjugate vaccine
• IL-12 immunotherapy
• Kinase inhibitors and anti-angiogenic treatment.

Explore other issues too, including these forces shaping that industry and market:
• Monoclonal antibodies (mAbs), cancer vaccines and antibody-drug conjugates
• Prevalence and incidence of ovarian cancer - expanding patient populations
• Competition from generic drugs and pressure from governmental price regulation
• Alliances, mergers and acquisitions (M&A) - changes in the industry.

Our study shows progress in preventing, inhibiting and halting those neoplasms. You also gain SWOT, STEP and Porter's five forces analyses.

Ovarian cancer R&D holds strength, variety and promise. See, then, what's possible for big pharma companies and specialists in biological drugs and related biotechnologies.

Companies and overall 2019 market value - what revenues possible?
Our work predicts the world market for ovarian cancer-treating drugs will reach $1.71bn in 2019. That industry will achieve strong revenue expansion from 2015 to 2025. With our analysis you find how high sales can go, seeing what is possible for those drug producers.
 
You also discover what companies hold most potential. For those therapies, explore pharmaceutical developers, producers and marketers, including these firms:
• Roche
• AstraZeneca
• Johnson & Johnson
• Zeltia
• Chugai.

You find 127 organisations mentioned. Also see interviews with Prima BioMed, OXiGENE and VBL Therapeutics. Discover what the future holds for companies treating those disorders of the ovary.

Ways Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025 helps you
Our new investigation benefits your work in these seven main ways, helping you stay ahead:
• Revenues for ovarian cancer treatments to 2025 - assess that overall world market's potential, seeing scope for investments, developments and marketing
• Submarket revenues to 2025 for chemotherapy, targeted therapies, immunotherapy and hormonal drugs - explore segments, seeing their sales outlooks
• Products' sales to 2025 - discover predicted revenues of Avastin, Lynparza and Yondelis, seeing how those medicines can compete and succeed
• National market forecasting to 2025 for 11 countries in the Americas, Europe and Asia - explore the best regions for treatment demand, sales and growth
• R&D activities - see progress, trends and prospects in that oncological research and development, finding technological, clinical and commercial possibilities
• Companies, news and opinions - examine participants in that rising market, and gain three interviews, helping your reputation for insight and staying ahead
• Analysis of what stimulates and restrains that industry and market - assess challenges and strengths there, helping you compete and gain advantages.

That survey, by our in-house UK-based analysts, gives knowledge to benefit your research, analyses, plans, decisions and proposals. It shows information you find nowhere else.

Discover predictions for treating ovarian cancer, getting information to help you now
With our independent analyses you explore products, companies, progress and possibilities. Discover the best commercial opportunities, as well as ways to help patients.

Having that data means you are less likely to fall behind in knowledge or miss opportunity. Through your choice now, find how you could save time and effort, also benefiting your plans, decisions, presentations, proposals and authority.

Try that study. Our investigation shows data, trends, opportunities and sales forecasts for that strong, expanding drugs market. So avoid missing out - please get our new report here now.

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

To request an exec summary of this report please email Sara Peerun at sara.peerun@visiongainglobal.com or call Tel: +44 (0) 20 7336 6100

Or click on https://goo.gl/jeXGQj

Organisations Mentioned in the Report 

AbbVie

Actavis

Advaxis

Aeterna Zentaris

Alios BioPharma (part of J&J)

Almirall

American Cancer Society

American Society of Clinical Oncology

Amgen

Angstrom Pharma

Array BipPharma

Astellas Pharma

Astex Pharmaceuticals

AstraZeneca

Australia and New Zealand Gynecological Oncology Group (ANZGOG)

Autorità Garante della Concorrenza e del Mercato (Italian Competition Authority)

Auven Therapeutics

AVAX Technologies

Baxter Healthcare

Boehringer Ingelheim

Bristol-Myers Squibb

Busto Arisizio Hospital [Italy]

Cancer Research Institute

Cancer Research UK

Cancer Treatment Centers of America

CASI Pharmaceuticals

Celgene

Cell Therapeutics

Celsion Corporation

Cerulean Pharma

Chiba University Hospital

Clovis Oncology

CTI BioPharma (formerly Cell Therapeutics)

Eisai

Eli Lilly

ENGOT

EntreMed (now CASI Pharmaceuticals)

European Commission (EC)

Expression Genetics

Facing Our Risk of Cancer Empowered (FORCE)

Food and Drug Administration [US]

Fox Chase Cancer Center

Fresenius Biotech North America

Galena Biopharma

GCIG

Genia (part of Roche)

Genentech

GlaxoSmithKline

Gradalis

Grupo Español de Investigación en Cáncer de Ovario (GEICO)

Gynecologic Oncology Group

Immunovaccine

Immutep

Incyte

Indiana University School of Medicine

InterMune (part of Roche)

International Agency for Research on Cancer (IARC)

International Gynecologic Cancer Society (IGCS)

Janssen Biotech (part of Janssen Pharmaceutical Companies)

Janssen Pharmaceutical (part of J&J)

Janssen Products (part of Janssen Pharmaceutical Companies)

Jiangsu Hengrui Med

Johnson & Johnson (J&J)

Jubilant Biosys

Ludwig Institute for Cancer Research

MabVax Therapeutics

Marshall Edwards (now MEI Pharma)

Massachusetts General Hospital

McGill University

Medical Research Council [UK]

Medical University Innsbruck

MedImmune (part of AstraZeneca)

MEI Pharma (part of Novogen)

Memorial Sloan-Kettering Cancer Center

Menarini Group

Merck & Co.

Morphotek, Inc. (part of Eisai)

Myriad Genetics

National Cancer Institute [US]

National Health and Medical Research Council [Australia]

National Health Service (NHS) [UK]

NCIC Clinical Trials Group

National Institute for Health and Care Excellence (NICE) [UK]

National Institutes of Health (NIH) [US]

National Institutes of Health Clinical Center (NIHCC) [US]

Nektar Therapeutics

Neopharm Group

Nordic Society for Oncology

Novartis

Novogen

NRG Oncology

OBI Pharma

Oncolytics Biotech

Onconova Therapeutics

Orion Genomics

OXiGENE

Peter MacCallum Cancer Centre

PharmaMar (part of Zeltia Group)

Poniard Pharmaceuticals

Prima BioMed

Quest PharmaTech

Roche

Roxane

Sandoz (part of Novartis)

Sanofi

Santaris (part of Roche)

SCRI Development Innovations

Seragon Pharmaceuticals (part of Roche)

Society of Gynecologic Oncology

Spirogen

Stanford University

Sunesis Pharmaceuticals

Surveillance, Epidemiology and End Results Program (SEER) [US]

Synta Pharmaceuticals

Taiho Pharmaceutical

Takeda Pharmaceuticals

TESARO

University College London

University of Queensland's Institute for Molecular Biosciences (IMB)

Vascular Biogenics Ltd (VBL Therapeutics)

VBL Therapeutics

VentiRx Pharmaceuticals

Westmead Millennium Institute for Medical Research

World Cancer Research Fund International

Worldwide Cancer Research

Zeltia Group

Zybrestat

SOURCE Visiongain